CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 308 enrolled
Drug / intervention
mRNA-1273 +4 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05397223
NCT05397223Phase 1Completed
CompareCT.gov

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults

ModernaTX, Inc.·interventional·Posted May 31, 2022·Updated Mar 12, 2026

In Brief

A Phase 1 clinical trial evaluating mRNA-1273, mRNA-1010, and 3 other interventions for SARS-CoV-2 and 3 related conditions. Completed, enrolled 308 participants across 8 sites.

Detailed Summary

The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedMay 31, 2022
Enrollment StartMay 24, 2022
Primary CompletionFeb 27, 2026
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 4.1 years ago

Interventions

mRNA-1273biological

Sterile liquid for injection

mRNA-1010biological

Sterile liquid for injection

mRNA-1345biological

Sterile liquid for injection

FLUAD®biological

adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine

mRNA-1647biological

Sterile lyophilized product